Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

Exclusion Criteria

• •Diagnosis of acute promyelocytic leukemia.
• •Known BCR-ABL-positive leukemia.
• •AML secondary to prior chemotherapy for other neoplasms (except for MDS).
• •AML that has relapsed after or is refractory to more than 2 lines of therapy.
• •Clinically active central nervous system leukemia or prior history of NCI CTCAE Grade ≥ 3 drug-related CNS toxicity.
• •Major surgery or radiation therapy within 4 weeks prior to the first study dose.
• •Prior treatment with iadademstat is not allowed. Treatment with any other agents with KDM1A/LSD1 inhibitory activity is only allowed if treatment finalized at least 3 weeks prior to first dose on study. Previous treatment with FLT3 inhibitors is allowed in the following cases: midostaurin and sorafenib are allowed when used in first-line therapy regimen as part of induction, consolidation and/or maintenance: quizartinib and gilteritinib are allowed when used in first-line therapy regimen, as part of induction, consolidation and/or maintenance, ONLY if patients were not refractory to the drugs or if responding, relapse did not occur while on these drugs.
• •Prior treatment with 3 or more lines of AML therapy.
• •Treatment with any investigational products within 3 weeks prior to first dose of study treatment.
• •Uncontrolled hypertension or poorly controlled diabetes.
• •Evidence of active uncontrolled viral, bacterial, or systemic fungal infection.
• •Pregnant or lactating women.